We chase Six Sigma in manufacturing and compliance—aiming for 99.999% efficiency—while accepting 66% productivity or less from leadership and project teams. That’s what we call the Expensive Asset Paradox.
Tech Project Leaders are feeling a lot less bullish these days. That is the inescapable conclusion from our latest research.
R&D Frameworks like AstraZeneca’s ‘5Rs’ has significantly boosted success. Yet, adding to the 5 Rights can further boost R&D Productivity.
Too many leaders dread the next project review. That has surprising implications for project success. It even has the potential to undermine the critical link between project and business success.
What are the top 5 ideas, according to advance readers of Pharma Super Projects? Let’s quickly explore them here.
Are you giving your strategic portfolio its needs? Here is a list of 12 tell-tale signs that your strategic portfolio needs attention.
In the race to implement AI, organizations need to balance throttle with traction. Find out how.
Ambition is up and confidence is down, but is there a new pragmatism in banking transformation? Find out why that matters.
In this webinar, Joe Renny (CatSci) and Ray Collis (Growth Pitstop) explore a novel but effective way to boost R&D productivity. The result is a protocol […]